Patheon Signs Three Year $18 Million Development Agreement with Boehringer Ingelheim
Patheon, Inc. announced that Boehringer Ingelheim has awarded it two projects with combined revenue of more than $18 million over a three year period of time. The projects are both fixed-dose combination drugs in development for the treatment of the growing population of Type II diabetics.
In commenting on the announcement, Mark Kontny, Patheon's President of Pharmaceutical Development Services and Chief Scientific Officer said, "I am very gratified that Boehringer Ingelheim recognizes our knowledge in formulating, scaling, and successfully launching complex formulations such as these molecules. It is this kind of support and recognition that has enabled us to develop our position in pharmaceutical development services."
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
